Dr. Neil Bressler discusses a post hoc analysis of DRCR.net's Protocol T, a 2-year comparative efficacy randomized clinical trial of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema (DME). The original Protocol T study showed that 2-year vision gains were comparable between all 3 drugs for center-involved DME. This post hoc analysis showed that for eyes with initial visual acuity 20/50 or worse, aflibercept led to greater mean visual acuity (VA) improvement at 2 years compared with bevacizumab or ranibizumab. When baseline VA loss was mild (20/32 to 20/40), there was little difference in visual outcomes between the 3 anti-VEGF agents.